Menu

Safety guide · 2 min read

Most GLP-1 side effects are digestive, but some need urgent care.

The short answer

Nausea, diarrhea, vomiting and constipation are the most common GLP-1 side effects. They are often mild and tend to appear while the dose goes up. Some symptoms need prompt care: severe stomach pain that does not ease, signs of dehydration, yellow skin or eyes, a swollen face or throat, or trouble breathing. Contact your prescribing clinician before changing any dose.

Livozo expects to offer clinician-reviewed access to semaglutide and tirzepatide through a licensed clinical partner. Care is not live today. This guide does not recommend a specific medication.

Common side effects

The Wegovy label lists nausea, diarrhea, vomiting, constipation, stomach pain, headache, tiredness, indigestion and dizziness among the most common side effects. Burping, bloating, reflux and hair loss also appear on the list.[1]

In the large trials of branded semaglutide and tirzepatide, most digestive side effects were mild to moderate. They happened mostly while the dose was being increased and often eased with time.[3][4]

Serious warnings on the labels

The branded labels warn about pancreatitis, gallbladder disease, kidney injury from dehydration and serious allergic reactions. They also warn about low blood sugar when a GLP-1 is used with insulin or some diabetes pills.[1][2]

Both labels carry a boxed warning about thyroid C-cell tumors seen in rodents. It is not known whether this happens in people. Tell a clinician about a lump in your neck, trouble swallowing, a hoarse voice or shortness of breath.[1][2]

The labels also warn that food may stay in the stomach during anesthesia or deep sedation. Tell your surgical and anesthesia team that you take a GLP-1 before any planned procedure.[1][2]

Extra risks with compounded products

FDA has received reports of people taking too much compounded semaglutide by mistake. Confusion between milliliters, milligrams and units, and syringes that were too large, played a part. Reported harms included severe nausea, vomiting, dehydration, pancreatitis and hospital stays.[5]

Compounded GLP-1s are not FDA-approved, and FDA has received adverse event reports linked to them. Ask the pharmacist to show you how to measure each dose.[6]

What to do if side effects start

Contact the prescribing clinician. Do not change your dose or schedule on your own. Small steps, such as eating smaller meals and drinking enough fluids, may help, but ask your clinician what fits you.

You can also report a side effect to FDA through its MedWatch program. Patients and health professionals can both file reports.

What we know

  • Digestive side effects are the most common and often ease over time.
  • The branded labels list serious warnings, including pancreatitis, gallbladder disease and kidney injury from dehydration.
  • FDA has reported dosing errors with compounded semaglutide that led to hospital care.

What we don't know yet

  • Whether the thyroid tumors seen in rodents also occur in people.
  • Long-term effects beyond the length of current trials.
  • How side effect rates for compounded products compare with branded ones.

Safety

  • Call emergency services for trouble breathing, a swollen face or throat, or fainting.
  • Seek urgent care for severe stomach pain that does not ease, with or without vomiting.
  • Seek prompt care for signs of dehydration, such as very little urine or dizziness, or for yellow skin or eyes.
  • Do not change a dose without guidance from the prescribing clinician.

This guide is education, not medical advice. It does not create a clinician-patient relationship. If you think you are having an emergency, call 911.

Sources

  1. DailyMed (NLM) — Wegovy (semaglutide) prescribing information
  2. DailyMed (NLM) — Zepbound (tirzepatide) prescribing information
  3. Wilding et al. — Once-weekly semaglutide in adults with overweight or obesity (STEP 1). N Engl J Med, 2021
  4. Jastreboff et al. — Tirzepatide once weekly for the treatment of obesity (SURMOUNT-1). N Engl J Med, 2022
  5. FDA — Dosing errors associated with compounded injectable semaglutide products
  6. FDA — FDA's concerns with unapproved GLP-1 drugs used for weight loss

Keep reading.